Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S in recurrent platinum-sensitive ovarian cancer
NCT07564141Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of rinatabart sesutecan in ovarian cancer, sponsored by Genmab. Started Aug 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07564141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564141.